nodes	percent_of_prediction	percent_of_DWPC	metapath
Plerixafor—CXCR4—hematologic cancer	0.692	1	CbGaD
Plerixafor—CXCR4—hematopoietic system—hematologic cancer	0.00542	0.261	CbGeAlD
Plerixafor—CXCR4—blood—hematologic cancer	0.00359	0.173	CbGeAlD
Plerixafor—CXCR4—bone marrow—hematologic cancer	0.00348	0.167	CbGeAlD
Plerixafor—CXCR4—lung—hematologic cancer	0.00315	0.152	CbGeAlD
Plerixafor—CXCR4—testis—hematologic cancer	0.00297	0.143	CbGeAlD
Plerixafor—CXCR4—lymph node—hematologic cancer	0.00215	0.104	CbGeAlD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—CCL2—hematologic cancer	8.23e-05	0.000659	CbGpPWpGaD
Plerixafor—CXCR4—Disease—IDH1—hematologic cancer	8.04e-05	0.000643	CbGpPWpGaD
Plerixafor—CXCR4—Disease—GSTO1—hematologic cancer	7.95e-05	0.000636	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—ARHGEF12—hematologic cancer	7.9e-05	0.000632	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—ADCY7—hematologic cancer	7.89e-05	0.000632	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PTHLH—hematologic cancer	7.86e-05	0.000629	CbGpPWpGaD
Plerixafor—CXCR4—Disease—AGO2—hematologic cancer	7.78e-05	0.000622	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—ARHGEF1—hematologic cancer	7.7e-05	0.000616	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HDAC9—hematologic cancer	7.69e-05	0.000616	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PTGER4—hematologic cancer	7.65e-05	0.000612	CbGpPWpGaD
Plerixafor—CXCR4—Disease—H3F3B—hematologic cancer	7.62e-05	0.00061	CbGpPWpGaD
Plerixafor—CXCR4—Disease—NPM1—hematologic cancer	7.33e-05	0.000587	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—CCL3—hematologic cancer	7.22e-05	0.000578	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PTHLH—hematologic cancer	7.14e-05	0.000571	CbGpPWpGaD
Plerixafor—CXCR4—Disease—FGF19—hematologic cancer	7.02e-05	0.000562	CbGpPWpGaD
Plerixafor—CXCR4—Disease—RPS14—hematologic cancer	6.97e-05	0.000558	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PTGER4—hematologic cancer	6.95e-05	0.000556	CbGpPWpGaD
Plerixafor—CXCR4—Disease—DKK1—hematologic cancer	6.91e-05	0.000553	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CCL17—hematologic cancer	6.9e-05	0.000552	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—AGRN—hematologic cancer	6.9e-05	0.000552	CbGpPWpGaD
Plerixafor—CXCR4—Disease—STAT5B—hematologic cancer	6.86e-05	0.000549	CbGpPWpGaD
Plerixafor—CXCR4—Disease—NUP98—hematologic cancer	6.86e-05	0.000549	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CXCR5—hematologic cancer	6.78e-05	0.000542	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CST3—hematologic cancer	6.71e-05	0.000537	CbGpPWpGaD
Plerixafor—CXCR4—Disease—ADCY7—hematologic cancer	6.66e-05	0.000533	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—LEF1—hematologic cancer	6.66e-05	0.000533	CbGpPWpGaD
Plerixafor—CXCR4—Disease—NUP214—hematologic cancer	6.61e-05	0.000529	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—GNA13—hematologic cancer	6.54e-05	0.000524	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—IL3—hematologic cancer	6.52e-05	0.000522	CbGpPWpGaD
Plerixafor—CXCR4—Disease—XIAP—hematologic cancer	6.48e-05	0.000518	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MTR—hematologic cancer	6.48e-05	0.000518	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TIAM1—hematologic cancer	6.44e-05	0.000515	CbGpPWpGaD
Plerixafor—CXCR4—Disease—ENO2—hematologic cancer	6.35e-05	0.000508	CbGpPWpGaD
Plerixafor—CXCR4—Disease—SMARCA4—hematologic cancer	6.31e-05	0.000505	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—RASGRP1—hematologic cancer	6.3e-05	0.000505	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—CCL2—hematologic cancer	6.27e-05	0.000502	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—JAK3—hematologic cancer	6.24e-05	0.0005	CbGpPWpGaD
Plerixafor—CXCR4—Disease—SDC1—hematologic cancer	6.02e-05	0.000482	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CXCL13—hematologic cancer	5.98e-05	0.000479	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CCR7—hematologic cancer	5.98e-05	0.000479	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—IL3—hematologic cancer	5.92e-05	0.000474	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NCOR2—hematologic cancer	5.91e-05	0.000473	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IL3RA—hematologic cancer	5.83e-05	0.000467	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CRKL—hematologic cancer	5.83e-05	0.000467	CbGpPWpGaD
Plerixafor—CXCR4—Disease—LCK—hematologic cancer	5.83e-05	0.000467	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—RASGRP1—hematologic cancer	5.72e-05	0.000458	CbGpPWpGaD
Plerixafor—CXCR4—Disease—H3F3A—hematologic cancer	5.72e-05	0.000458	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—GRB2—hematologic cancer	5.67e-05	0.000454	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—RGS2—hematologic cancer	5.63e-05	0.00045	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TRIO—hematologic cancer	5.56e-05	0.000445	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CMA1—hematologic cancer	5.56e-05	0.000445	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TRH—hematologic cancer	5.56e-05	0.000445	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PRKCZ—hematologic cancer	5.56e-05	0.000445	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CALR—hematologic cancer	5.46e-05	0.000437	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—AGO2—hematologic cancer	5.44e-05	0.000436	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—SPHK1—hematologic cancer	5.44e-05	0.000436	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—LPAR1—hematologic cancer	5.39e-05	0.000431	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—HDAC9—hematologic cancer	5.39e-05	0.000431	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PARP1—hematologic cancer	5.37e-05	0.00043	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—H3F3B—hematologic cancer	5.33e-05	0.000427	CbGpPWpGaD
Plerixafor—CXCR4—Disease—FBXW7—hematologic cancer	5.28e-05	0.000423	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HDAC2—hematologic cancer	5.18e-05	0.000414	CbGpPWpGaD
Plerixafor—Malaise—Prednisone—hematologic cancer	5.17e-05	0.000319	CcSEcCtD
Plerixafor—Abdominal pain—Etoposide—hematologic cancer	5.16e-05	0.000318	CcSEcCtD
Plerixafor—Haemorrhage—Epirubicin—hematologic cancer	5.15e-05	0.000318	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—GRB2—hematologic cancer	5.15e-05	0.000412	CbGpPWpGaD
Plerixafor—Syncope—Prednisone—hematologic cancer	5.14e-05	0.000317	CcSEcCtD
Plerixafor—Vomiting—Vincristine—hematologic cancer	5.12e-05	0.000316	CcSEcCtD
Plerixafor—CXCR4—Disease—CD44—hematologic cancer	5.12e-05	0.00041	CbGpPWpGaD
Plerixafor—Urticaria—Prednisolone—hematologic cancer	5.11e-05	0.000315	CcSEcCtD
Plerixafor—Asthenia—Cisplatin—hematologic cancer	5.11e-05	0.000315	CcSEcCtD
Plerixafor—Fatigue—Triamcinolone—hematologic cancer	5.1e-05	0.000315	CcSEcCtD
Plerixafor—Rash—Vincristine—hematologic cancer	5.08e-05	0.000313	CcSEcCtD
Plerixafor—Dermatitis—Vincristine—hematologic cancer	5.08e-05	0.000313	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—CSF2—hematologic cancer	5.07e-05	0.000405	CbGpPWpGaD
Plerixafor—Pain—Triamcinolone—hematologic cancer	5.06e-05	0.000312	CcSEcCtD
Plerixafor—Connective tissue disorder—Epirubicin—hematologic cancer	5.06e-05	0.000312	CcSEcCtD
Plerixafor—Headache—Vincristine—hematologic cancer	5.05e-05	0.000311	CcSEcCtD
Plerixafor—CXCR4—Disease—CBL—hematologic cancer	5.05e-05	0.000404	CbGpPWpGaD
Plerixafor—Loss of consciousness—Prednisone—hematologic cancer	5.04e-05	0.000311	CcSEcCtD
Plerixafor—Nausea—Carmustine—hematologic cancer	5.01e-05	0.000309	CcSEcCtD
Plerixafor—Vomiting—Mitoxantrone—hematologic cancer	4.99e-05	0.000308	CcSEcCtD
Plerixafor—Vomiting—Irinotecan—hematologic cancer	4.99e-05	0.000308	CcSEcCtD
Plerixafor—Immune system disorder—Methotrexate—hematologic cancer	4.97e-05	0.000307	CcSEcCtD
Plerixafor—Nausea—Alitretinoin—hematologic cancer	4.97e-05	0.000306	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PDE4B—hematologic cancer	4.96e-05	0.000397	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CNR2—hematologic cancer	4.96e-05	0.000397	CbGpPWpGaD
Plerixafor—Rash—Mitoxantrone—hematologic cancer	4.95e-05	0.000305	CcSEcCtD
Plerixafor—Rash—Irinotecan—hematologic cancer	4.95e-05	0.000305	CcSEcCtD
Plerixafor—Dermatitis—Mitoxantrone—hematologic cancer	4.94e-05	0.000305	CcSEcCtD
Plerixafor—Dermatitis—Irinotecan—hematologic cancer	4.94e-05	0.000305	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—FGF19—hematologic cancer	4.92e-05	0.000394	CbGpPWpGaD
Plerixafor—Headache—Mitoxantrone—hematologic cancer	4.92e-05	0.000303	CcSEcCtD
Plerixafor—Headache—Irinotecan—hematologic cancer	4.92e-05	0.000303	CcSEcCtD
Plerixafor—Nausea—Ifosfamide—hematologic cancer	4.91e-05	0.000303	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Betamethasone—hematologic cancer	4.89e-05	0.000302	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	4.89e-05	0.000302	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—PRKCG—hematologic cancer	4.89e-05	0.000391	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—JAK1—hematologic cancer	4.89e-05	0.000391	CbGpPWpGaD
Plerixafor—Arthralgia—Prednisone—hematologic cancer	4.88e-05	0.000301	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—RAC2—hematologic cancer	4.88e-05	0.000391	CbGpPWpGaD
Plerixafor—Feeling abnormal—Triamcinolone—hematologic cancer	4.88e-05	0.000301	CcSEcCtD
Plerixafor—Diarrhoea—Cisplatin—hematologic cancer	4.87e-05	0.000301	CcSEcCtD
Plerixafor—Vomiting—Gemcitabine—hematologic cancer	4.86e-05	0.0003	CcSEcCtD
Plerixafor—Insomnia—Dexamethasone—hematologic cancer	4.86e-05	0.0003	CcSEcCtD
Plerixafor—Insomnia—Betamethasone—hematologic cancer	4.86e-05	0.0003	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	4.85e-05	0.000299	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—DKK1—hematologic cancer	4.84e-05	0.000387	CbGpPWpGaD
Plerixafor—Paraesthesia—Dexamethasone—hematologic cancer	4.82e-05	0.000297	CcSEcCtD
Plerixafor—Paraesthesia—Betamethasone—hematologic cancer	4.82e-05	0.000297	CcSEcCtD
Plerixafor—Discomfort—Prednisone—hematologic cancer	4.82e-05	0.000297	CcSEcCtD
Plerixafor—Mental disorder—Methotrexate—hematologic cancer	4.82e-05	0.000297	CcSEcCtD
Plerixafor—Rash—Gemcitabine—hematologic cancer	4.82e-05	0.000297	CcSEcCtD
Plerixafor—Dermatitis—Gemcitabine—hematologic cancer	4.81e-05	0.000297	CcSEcCtD
Plerixafor—CXCR4—Disease—HSP90AA1—hematologic cancer	4.81e-05	0.000385	CbGpPWpGaD
Plerixafor—Hypersensitivity—Etoposide—hematologic cancer	4.81e-05	0.000297	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—STAT5B—hematologic cancer	4.8e-05	0.000384	CbGpPWpGaD
Plerixafor—Erythema—Methotrexate—hematologic cancer	4.79e-05	0.000295	CcSEcCtD
Plerixafor—Haemoglobin—Doxorubicin—hematologic cancer	4.79e-05	0.000295	CcSEcCtD
Plerixafor—Headache—Gemcitabine—hematologic cancer	4.79e-05	0.000295	CcSEcCtD
Plerixafor—Nausea—Vincristine—hematologic cancer	4.79e-05	0.000295	CcSEcCtD
Plerixafor—Haemorrhage—Doxorubicin—hematologic cancer	4.76e-05	0.000294	CcSEcCtD
Plerixafor—Hypersensitivity—Prednisolone—hematologic cancer	4.74e-05	0.000292	CcSEcCtD
Plerixafor—Dyspepsia—Dexamethasone—hematologic cancer	4.73e-05	0.000292	CcSEcCtD
Plerixafor—Dyspepsia—Betamethasone—hematologic cancer	4.73e-05	0.000292	CcSEcCtD
Plerixafor—Urticaria—Triamcinolone—hematologic cancer	4.7e-05	0.00029	CcSEcCtD
Plerixafor—Asthenia—Etoposide—hematologic cancer	4.68e-05	0.000289	CcSEcCtD
Plerixafor—Connective tissue disorder—Doxorubicin—hematologic cancer	4.68e-05	0.000289	CcSEcCtD
Plerixafor—Anaphylactic shock—Prednisone—hematologic cancer	4.68e-05	0.000288	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—ADCY7—hematologic cancer	4.66e-05	0.000373	CbGpPWpGaD
Plerixafor—Nausea—Mitoxantrone—hematologic cancer	4.66e-05	0.000287	CcSEcCtD
Plerixafor—Nausea—Irinotecan—hematologic cancer	4.66e-05	0.000287	CcSEcCtD
Plerixafor—Immune system disorder—Epirubicin—hematologic cancer	4.65e-05	0.000287	CcSEcCtD
Plerixafor—CXCR4—Disease—STAT1—hematologic cancer	4.64e-05	0.000372	CbGpPWpGaD
Plerixafor—Gastrointestinal disorder—Dexamethasone—hematologic cancer	4.64e-05	0.000286	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Betamethasone—hematologic cancer	4.64e-05	0.000286	CcSEcCtD
Plerixafor—Fatigue—Betamethasone—hematologic cancer	4.63e-05	0.000286	CcSEcCtD
Plerixafor—Fatigue—Dexamethasone—hematologic cancer	4.63e-05	0.000286	CcSEcCtD
Plerixafor—Pruritus—Etoposide—hematologic cancer	4.62e-05	0.000285	CcSEcCtD
Plerixafor—Shock—Prednisone—hematologic cancer	4.6e-05	0.000284	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—CSF2—hematologic cancer	4.6e-05	0.000368	CbGpPWpGaD
Plerixafor—Pain—Betamethasone—hematologic cancer	4.59e-05	0.000283	CcSEcCtD
Plerixafor—Pain—Dexamethasone—hematologic cancer	4.59e-05	0.000283	CcSEcCtD
Plerixafor—Nervous system disorder—Prednisone—hematologic cancer	4.59e-05	0.000283	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—IL2RA—hematologic cancer	4.57e-05	0.000365	CbGpPWpGaD
Plerixafor—Skin disorder—Prednisone—hematologic cancer	4.54e-05	0.00028	CcSEcCtD
Plerixafor—Nausea—Gemcitabine—hematologic cancer	4.54e-05	0.00028	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—XIAP—hematologic cancer	4.54e-05	0.000363	CbGpPWpGaD
Plerixafor—Vomiting—Cisplatin—hematologic cancer	4.53e-05	0.000279	CcSEcCtD
Plerixafor—Hyperhidrosis—Prednisone—hematologic cancer	4.52e-05	0.000279	CcSEcCtD
Plerixafor—Mental disorder—Epirubicin—hematologic cancer	4.51e-05	0.000278	CcSEcCtD
Plerixafor—Rash—Cisplatin—hematologic cancer	4.49e-05	0.000277	CcSEcCtD
Plerixafor—Dermatitis—Cisplatin—hematologic cancer	4.49e-05	0.000277	CcSEcCtD
Plerixafor—Erythema—Epirubicin—hematologic cancer	4.48e-05	0.000276	CcSEcCtD
Plerixafor—Diarrhoea—Etoposide—hematologic cancer	4.47e-05	0.000275	CcSEcCtD
Plerixafor—Ill-defined disorder—Methotrexate—hematologic cancer	4.44e-05	0.000274	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—JAK1—hematologic cancer	4.44e-05	0.000355	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PRKCG—hematologic cancer	4.44e-05	0.000355	CbGpPWpGaD
Plerixafor—Feeling abnormal—Betamethasone—hematologic cancer	4.43e-05	0.000273	CcSEcCtD
Plerixafor—Feeling abnormal—Dexamethasone—hematologic cancer	4.43e-05	0.000273	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—SH2B3—hematologic cancer	4.42e-05	0.000354	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—SMARCA4—hematologic cancer	4.42e-05	0.000354	CbGpPWpGaD
Plerixafor—Flatulence—Epirubicin—hematologic cancer	4.42e-05	0.000272	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—GZMB—hematologic cancer	4.39e-05	0.000352	CbGpPWpGaD
Plerixafor—Gastrointestinal pain—Betamethasone—hematologic cancer	4.39e-05	0.000271	CcSEcCtD
Plerixafor—Gastrointestinal pain—Dexamethasone—hematologic cancer	4.39e-05	0.000271	CcSEcCtD
Plerixafor—Hypersensitivity—Triamcinolone—hematologic cancer	4.36e-05	0.000269	CcSEcCtD
Plerixafor—CXCR4—Disease—GRB2—hematologic cancer	4.34e-05	0.000348	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PDGFA—hematologic cancer	4.33e-05	0.000347	CbGpPWpGaD
Plerixafor—Malaise—Methotrexate—hematologic cancer	4.32e-05	0.000266	CcSEcCtD
Plerixafor—Dizziness—Etoposide—hematologic cancer	4.32e-05	0.000266	CcSEcCtD
Plerixafor—Immune system disorder—Doxorubicin—hematologic cancer	4.3e-05	0.000265	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—CTNNA1—hematologic cancer	4.29e-05	0.000343	CbGpPWpGaD
Plerixafor—CXCR4—Disease—KITLG—hematologic cancer	4.27e-05	0.000342	CbGpPWpGaD
Plerixafor—Urticaria—Betamethasone—hematologic cancer	4.27e-05	0.000263	CcSEcCtD
Plerixafor—Urticaria—Dexamethasone—hematologic cancer	4.27e-05	0.000263	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—EIF4EBP1—hematologic cancer	4.26e-05	0.000341	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—HSPB1—hematologic cancer	4.26e-05	0.000341	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CCL3—hematologic cancer	4.26e-05	0.000341	CbGpPWpGaD
Plerixafor—Musculoskeletal discomfort—Prednisone—hematologic cancer	4.26e-05	0.000263	CcSEcCtD
Plerixafor—Dizziness—Prednisolone—hematologic cancer	4.26e-05	0.000263	CcSEcCtD
Plerixafor—Asthenia—Triamcinolone—hematologic cancer	4.25e-05	0.000262	CcSEcCtD
Plerixafor—Abdominal pain—Betamethasone—hematologic cancer	4.25e-05	0.000262	CcSEcCtD
Plerixafor—Abdominal pain—Dexamethasone—hematologic cancer	4.25e-05	0.000262	CcSEcCtD
Plerixafor—Nausea—Cisplatin—hematologic cancer	4.23e-05	0.000261	CcSEcCtD
Plerixafor—Insomnia—Prednisone—hematologic cancer	4.23e-05	0.000261	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—SDC1—hematologic cancer	4.22e-05	0.000338	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PTHLH—hematologic cancer	4.22e-05	0.000338	CbGpPWpGaD
Plerixafor—Paraesthesia—Prednisone—hematologic cancer	4.2e-05	0.000259	CcSEcCtD
Plerixafor—Pruritus—Triamcinolone—hematologic cancer	4.19e-05	0.000258	CcSEcCtD
Plerixafor—Mental disorder—Doxorubicin—hematologic cancer	4.17e-05	0.000257	CcSEcCtD
Plerixafor—CXCR4—Disease—STAT5A—hematologic cancer	4.17e-05	0.000334	CbGpPWpGaD
Plerixafor—Ill-defined disorder—Epirubicin—hematologic cancer	4.16e-05	0.000256	CcSEcCtD
Plerixafor—Vomiting—Etoposide—hematologic cancer	4.15e-05	0.000256	CcSEcCtD
Plerixafor—Erythema—Doxorubicin—hematologic cancer	4.15e-05	0.000256	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—IL2RA—hematologic cancer	4.15e-05	0.000332	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CDKN2B—hematologic cancer	4.14e-05	0.000331	CbGpPWpGaD
Plerixafor—Dyspepsia—Prednisone—hematologic cancer	4.12e-05	0.000254	CcSEcCtD
Plerixafor—Rash—Etoposide—hematologic cancer	4.11e-05	0.000254	CcSEcCtD
Plerixafor—Dermatitis—Etoposide—hematologic cancer	4.11e-05	0.000254	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PTGER4—hematologic cancer	4.1e-05	0.000329	CbGpPWpGaD
Plerixafor—Headache—Etoposide—hematologic cancer	4.09e-05	0.000252	CcSEcCtD
Plerixafor—Flatulence—Doxorubicin—hematologic cancer	4.09e-05	0.000252	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—LCK—hematologic cancer	4.08e-05	0.000327	CbGpPWpGaD
Plerixafor—Arthralgia—Methotrexate—hematologic cancer	4.08e-05	0.000251	CcSEcCtD
Plerixafor—Rash—Prednisolone—hematologic cancer	4.06e-05	0.00025	CcSEcCtD
Plerixafor—Dermatitis—Prednisolone—hematologic cancer	4.05e-05	0.00025	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	4.05e-05	0.00025	CcSEcCtD
Plerixafor—Malaise—Epirubicin—hematologic cancer	4.04e-05	0.000249	CcSEcCtD
Plerixafor—Fatigue—Prednisone—hematologic cancer	4.03e-05	0.000249	CcSEcCtD
Plerixafor—Headache—Prednisolone—hematologic cancer	4.03e-05	0.000249	CcSEcCtD
Plerixafor—Discomfort—Methotrexate—hematologic cancer	4.03e-05	0.000248	CcSEcCtD
Plerixafor—Syncope—Epirubicin—hematologic cancer	4.02e-05	0.000248	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—H3F3A—hematologic cancer	4e-05	0.00032	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CD86—hematologic cancer	4e-05	0.00032	CbGpPWpGaD
Plerixafor—Constipation—Prednisone—hematologic cancer	4e-05	0.000247	CcSEcCtD
Plerixafor—CXCR4—Disease—HES1—hematologic cancer	3.95e-05	0.000316	CbGpPWpGaD
Plerixafor—Loss of consciousness—Epirubicin—hematologic cancer	3.94e-05	0.000243	CcSEcCtD
Plerixafor—CXCR4—Disease—NCOR1—hematologic cancer	3.92e-05	0.000314	CbGpPWpGaD
Plerixafor—Dizziness—Triamcinolone—hematologic cancer	3.91e-05	0.000241	CcSEcCtD
Plerixafor—Anaphylactic shock—Methotrexate—hematologic cancer	3.91e-05	0.000241	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PRKCZ—hematologic cancer	3.89e-05	0.000311	CbGpPWpGaD
Plerixafor—CXCR4—Disease—FGF1—hematologic cancer	3.88e-05	0.000311	CbGpPWpGaD
Plerixafor—Nausea—Etoposide—hematologic cancer	3.88e-05	0.000239	CcSEcCtD
Plerixafor—Feeling abnormal—Prednisone—hematologic cancer	3.85e-05	0.000238	CcSEcCtD
Plerixafor—Asthenia—Betamethasone—hematologic cancer	3.85e-05	0.000238	CcSEcCtD
Plerixafor—Asthenia—Dexamethasone—hematologic cancer	3.85e-05	0.000238	CcSEcCtD
Plerixafor—Ill-defined disorder—Doxorubicin—hematologic cancer	3.85e-05	0.000237	CcSEcCtD
Plerixafor—Nervous system disorder—Methotrexate—hematologic cancer	3.83e-05	0.000236	CcSEcCtD
Plerixafor—Gastrointestinal pain—Prednisone—hematologic cancer	3.82e-05	0.000236	CcSEcCtD
Plerixafor—CXCR4—Disease—FOXO1—hematologic cancer	3.82e-05	0.000306	CbGpPWpGaD
Plerixafor—Nausea—Prednisolone—hematologic cancer	3.82e-05	0.000236	CcSEcCtD
Plerixafor—CXCR4—Disease—PDGFRB—hematologic cancer	3.82e-05	0.000306	CbGpPWpGaD
Plerixafor—Arthralgia—Epirubicin—hematologic cancer	3.82e-05	0.000235	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CG—hematologic cancer	3.8e-05	0.000304	CbGpPWpGaD
Plerixafor—Pruritus—Betamethasone—hematologic cancer	3.8e-05	0.000234	CcSEcCtD
Plerixafor—Pruritus—Dexamethasone—hematologic cancer	3.8e-05	0.000234	CcSEcCtD
Plerixafor—Skin disorder—Methotrexate—hematologic cancer	3.8e-05	0.000234	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	3.79e-05	0.000234	CcSEcCtD
Plerixafor—Hyperhidrosis—Methotrexate—hematologic cancer	3.78e-05	0.000233	CcSEcCtD
Plerixafor—Discomfort—Epirubicin—hematologic cancer	3.77e-05	0.000233	CcSEcCtD
Plerixafor—Vomiting—Triamcinolone—hematologic cancer	3.76e-05	0.000232	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PARP1—hematologic cancer	3.76e-05	0.000301	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PDGFRA—hematologic cancer	3.76e-05	0.000301	CbGpPWpGaD
Plerixafor—CXCR4—Disease—JAK1—hematologic cancer	3.75e-05	0.0003	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PRKCG—hematologic cancer	3.75e-05	0.0003	CbGpPWpGaD
Plerixafor—Malaise—Doxorubicin—hematologic cancer	3.74e-05	0.000231	CcSEcCtD
Plerixafor—Rash—Triamcinolone—hematologic cancer	3.73e-05	0.00023	CcSEcCtD
Plerixafor—Dry mouth—Epirubicin—hematologic cancer	3.73e-05	0.00023	CcSEcCtD
Plerixafor—Dermatitis—Triamcinolone—hematologic cancer	3.73e-05	0.00023	CcSEcCtD
Plerixafor—Syncope—Doxorubicin—hematologic cancer	3.72e-05	0.000229	CcSEcCtD
Plerixafor—Urticaria—Prednisone—hematologic cancer	3.72e-05	0.000229	CcSEcCtD
Plerixafor—Headache—Triamcinolone—hematologic cancer	3.71e-05	0.000229	CcSEcCtD
Plerixafor—Abdominal pain—Prednisone—hematologic cancer	3.7e-05	0.000228	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—FBXW7—hematologic cancer	3.7e-05	0.000296	CbGpPWpGaD
Plerixafor—Diarrhoea—Betamethasone—hematologic cancer	3.67e-05	0.000227	CcSEcCtD
Plerixafor—Diarrhoea—Dexamethasone—hematologic cancer	3.67e-05	0.000227	CcSEcCtD
Plerixafor—Anaphylactic shock—Epirubicin—hematologic cancer	3.66e-05	0.000226	CcSEcCtD
Plerixafor—Loss of consciousness—Doxorubicin—hematologic cancer	3.65e-05	0.000225	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—HDAC2—hematologic cancer	3.63e-05	0.00029	CbGpPWpGaD
Plerixafor—Shock—Epirubicin—hematologic cancer	3.6e-05	0.000222	CcSEcCtD
Plerixafor—Nervous system disorder—Epirubicin—hematologic cancer	3.59e-05	0.000221	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Methotrexate—hematologic cancer	3.56e-05	0.00022	CcSEcCtD
Plerixafor—Skin disorder—Epirubicin—hematologic cancer	3.55e-05	0.000219	CcSEcCtD
Plerixafor—Dizziness—Dexamethasone—hematologic cancer	3.55e-05	0.000219	CcSEcCtD
Plerixafor—Dizziness—Betamethasone—hematologic cancer	3.55e-05	0.000219	CcSEcCtD
Plerixafor—Hyperhidrosis—Epirubicin—hematologic cancer	3.54e-05	0.000218	CcSEcCtD
Plerixafor—Insomnia—Methotrexate—hematologic cancer	3.54e-05	0.000218	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—CBL—hematologic cancer	3.53e-05	0.000283	CbGpPWpGaD
Plerixafor—Arthralgia—Doxorubicin—hematologic cancer	3.53e-05	0.000218	CcSEcCtD
Plerixafor—Nausea—Triamcinolone—hematologic cancer	3.52e-05	0.000217	CcSEcCtD
Plerixafor—Paraesthesia—Methotrexate—hematologic cancer	3.51e-05	0.000216	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	3.51e-05	0.000216	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—IL3—hematologic cancer	3.5e-05	0.00028	CbGpPWpGaD
Plerixafor—Discomfort—Doxorubicin—hematologic cancer	3.49e-05	0.000215	CcSEcCtD
Plerixafor—Dyspnoea—Methotrexate—hematologic cancer	3.49e-05	0.000215	CcSEcCtD
Plerixafor—CXCR4—Disease—MTHFR—hematologic cancer	3.47e-05	0.000278	CbGpPWpGaD
Plerixafor—CXCR4—Disease—TERT—hematologic cancer	3.46e-05	0.000277	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HLA-A—hematologic cancer	3.46e-05	0.000277	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CG—hematologic cancer	3.45e-05	0.000276	CbGpPWpGaD
Plerixafor—Dry mouth—Doxorubicin—hematologic cancer	3.45e-05	0.000213	CcSEcCtD
Plerixafor—Hypersensitivity—Prednisone—hematologic cancer	3.45e-05	0.000213	CcSEcCtD
Plerixafor—Dyspepsia—Methotrexate—hematologic cancer	3.44e-05	0.000212	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PTPN1—hematologic cancer	3.44e-05	0.000275	CbGpPWpGaD
Plerixafor—Vomiting—Betamethasone—hematologic cancer	3.42e-05	0.000211	CcSEcCtD
Plerixafor—Vomiting—Dexamethasone—hematologic cancer	3.42e-05	0.000211	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—PTPN11—hematologic cancer	3.39e-05	0.000272	CbGpPWpGaD
Plerixafor—Rash—Dexamethasone—hematologic cancer	3.39e-05	0.000209	CcSEcCtD
Plerixafor—Rash—Betamethasone—hematologic cancer	3.39e-05	0.000209	CcSEcCtD
Plerixafor—Anaphylactic shock—Doxorubicin—hematologic cancer	3.38e-05	0.000209	CcSEcCtD
Plerixafor—Dermatitis—Dexamethasone—hematologic cancer	3.38e-05	0.000209	CcSEcCtD
Plerixafor—Dermatitis—Betamethasone—hematologic cancer	3.38e-05	0.000209	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—RASGRP1—hematologic cancer	3.38e-05	0.000271	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PDGFB—hematologic cancer	3.38e-05	0.00027	CbGpPWpGaD
Plerixafor—Gastrointestinal disorder—Methotrexate—hematologic cancer	3.37e-05	0.000208	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—HSP90AA1—hematologic cancer	3.37e-05	0.00027	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—SYK—hematologic cancer	3.37e-05	0.00027	CbGpPWpGaD
Plerixafor—Fatigue—Methotrexate—hematologic cancer	3.37e-05	0.000208	CcSEcCtD
Plerixafor—Headache—Dexamethasone—hematologic cancer	3.36e-05	0.000208	CcSEcCtD
Plerixafor—Headache—Betamethasone—hematologic cancer	3.36e-05	0.000208	CcSEcCtD
Plerixafor—Asthenia—Prednisone—hematologic cancer	3.36e-05	0.000207	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CD—hematologic cancer	3.34e-05	0.000268	CbGpPWpGaD
Plerixafor—Pain—Methotrexate—hematologic cancer	3.34e-05	0.000206	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Epirubicin—hematologic cancer	3.33e-05	0.000206	CcSEcCtD
Plerixafor—Shock—Doxorubicin—hematologic cancer	3.33e-05	0.000205	CcSEcCtD
Plerixafor—Nervous system disorder—Doxorubicin—hematologic cancer	3.32e-05	0.000205	CcSEcCtD
Plerixafor—Pruritus—Prednisone—hematologic cancer	3.31e-05	0.000204	CcSEcCtD
Plerixafor—Insomnia—Epirubicin—hematologic cancer	3.31e-05	0.000204	CcSEcCtD
Plerixafor—CXCR4—Disease—TSC2—hematologic cancer	3.3e-05	0.000264	CbGpPWpGaD
Plerixafor—Skin disorder—Doxorubicin—hematologic cancer	3.29e-05	0.000203	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—CREB1—hematologic cancer	3.29e-05	0.000263	CbGpPWpGaD
Plerixafor—Paraesthesia—Epirubicin—hematologic cancer	3.28e-05	0.000203	CcSEcCtD
Plerixafor—Hyperhidrosis—Doxorubicin—hematologic cancer	3.27e-05	0.000202	CcSEcCtD
Plerixafor—Dyspnoea—Epirubicin—hematologic cancer	3.26e-05	0.000201	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—STAT1—hematologic cancer	3.25e-05	0.00026	CbGpPWpGaD
Plerixafor—Feeling abnormal—Methotrexate—hematologic cancer	3.22e-05	0.000199	CcSEcCtD
Plerixafor—Dyspepsia—Epirubicin—hematologic cancer	3.22e-05	0.000199	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—CCL2—hematologic cancer	3.22e-05	0.000257	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—IL6R—hematologic cancer	3.21e-05	0.000257	CbGpPWpGaD
Plerixafor—Diarrhoea—Prednisone—hematologic cancer	3.2e-05	0.000197	CcSEcCtD
Plerixafor—Gastrointestinal pain—Methotrexate—hematologic cancer	3.2e-05	0.000197	CcSEcCtD
Plerixafor—Nausea—Dexamethasone—hematologic cancer	3.19e-05	0.000197	CcSEcCtD
Plerixafor—Nausea—Betamethasone—hematologic cancer	3.19e-05	0.000197	CcSEcCtD
Plerixafor—CXCR4—Disease—FGFR3—hematologic cancer	3.17e-05	0.000254	CbGpPWpGaD
Plerixafor—Gastrointestinal disorder—Epirubicin—hematologic cancer	3.16e-05	0.000195	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3R1—hematologic cancer	3.16e-05	0.000253	CbGpPWpGaD
Plerixafor—Fatigue—Epirubicin—hematologic cancer	3.15e-05	0.000195	CcSEcCtD
Plerixafor—Constipation—Epirubicin—hematologic cancer	3.13e-05	0.000193	CcSEcCtD
Plerixafor—Pain—Epirubicin—hematologic cancer	3.13e-05	0.000193	CcSEcCtD
Plerixafor—Urticaria—Methotrexate—hematologic cancer	3.11e-05	0.000192	CcSEcCtD
Plerixafor—Dizziness—Prednisone—hematologic cancer	3.09e-05	0.000191	CcSEcCtD
Plerixafor—Abdominal pain—Methotrexate—hematologic cancer	3.09e-05	0.000191	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	3.08e-05	0.00019	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—JAK2—hematologic cancer	3.07e-05	0.000246	CbGpPWpGaD
Plerixafor—Insomnia—Doxorubicin—hematologic cancer	3.06e-05	0.000189	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—MAP2K1—hematologic cancer	3.06e-05	0.000245	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—GRB2—hematologic cancer	3.04e-05	0.000243	CbGpPWpGaD
Plerixafor—Paraesthesia—Doxorubicin—hematologic cancer	3.04e-05	0.000187	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CD—hematologic cancer	3.04e-05	0.000243	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PDGFA—hematologic cancer	3.03e-05	0.000243	CbGpPWpGaD
Plerixafor—Dyspnoea—Doxorubicin—hematologic cancer	3.02e-05	0.000186	CcSEcCtD
Plerixafor—Feeling abnormal—Epirubicin—hematologic cancer	3.01e-05	0.000186	CcSEcCtD
Plerixafor—CXCR4—Disease—BAD—hematologic cancer	3.01e-05	0.000241	CbGpPWpGaD
Plerixafor—Gastrointestinal pain—Epirubicin—hematologic cancer	2.99e-05	0.000184	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—KITLG—hematologic cancer	2.99e-05	0.000239	CbGpPWpGaD
Plerixafor—Dyspepsia—Doxorubicin—hematologic cancer	2.98e-05	0.000184	CcSEcCtD
Plerixafor—CXCR4—Disease—NOTCH1—hematologic cancer	2.98e-05	0.000238	CbGpPWpGaD
Plerixafor—Vomiting—Prednisone—hematologic cancer	2.97e-05	0.000183	CcSEcCtD
Plerixafor—Rash—Prednisone—hematologic cancer	2.95e-05	0.000182	CcSEcCtD
Plerixafor—Dermatitis—Prednisone—hematologic cancer	2.95e-05	0.000182	CcSEcCtD
Plerixafor—Headache—Prednisone—hematologic cancer	2.93e-05	0.000181	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—STAT5A—hematologic cancer	2.92e-05	0.000234	CbGpPWpGaD
Plerixafor—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.92e-05	0.00018	CcSEcCtD
Plerixafor—CXCR4—Disease—CD80—hematologic cancer	2.92e-05	0.000234	CbGpPWpGaD
Plerixafor—Fatigue—Doxorubicin—hematologic cancer	2.92e-05	0.00018	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CB—hematologic cancer	2.91e-05	0.000233	CbGpPWpGaD
Plerixafor—CXCR4—Disease—KIT—hematologic cancer	2.91e-05	0.000233	CbGpPWpGaD
Plerixafor—Urticaria—Epirubicin—hematologic cancer	2.91e-05	0.000179	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—CDKN2B—hematologic cancer	2.9e-05	0.000232	CbGpPWpGaD
Plerixafor—Pain—Doxorubicin—hematologic cancer	2.89e-05	0.000179	CcSEcCtD
Plerixafor—Constipation—Doxorubicin—hematologic cancer	2.89e-05	0.000179	CcSEcCtD
Plerixafor—Abdominal pain—Epirubicin—hematologic cancer	2.89e-05	0.000178	CcSEcCtD
Plerixafor—Hypersensitivity—Methotrexate—hematologic cancer	2.88e-05	0.000178	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—PIK3R1—hematologic cancer	2.87e-05	0.00023	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PTPN11—hematologic cancer	2.86e-05	0.000229	CbGpPWpGaD
Plerixafor—Asthenia—Methotrexate—hematologic cancer	2.8e-05	0.000173	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—CD86—hematologic cancer	2.8e-05	0.000224	CbGpPWpGaD
Plerixafor—Feeling abnormal—Doxorubicin—hematologic cancer	2.79e-05	0.000172	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—JAK2—hematologic cancer	2.79e-05	0.000223	CbGpPWpGaD
Plerixafor—Nausea—Prednisone—hematologic cancer	2.78e-05	0.000171	CcSEcCtD
Plerixafor—CXCR4—Disease—CREB1—hematologic cancer	2.77e-05	0.000222	CbGpPWpGaD
Plerixafor—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.77e-05	0.000171	CcSEcCtD
Plerixafor—Pruritus—Methotrexate—hematologic cancer	2.77e-05	0.000171	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—HES1—hematologic cancer	2.76e-05	0.000221	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NCOR1—hematologic cancer	2.75e-05	0.00022	CbGpPWpGaD
Plerixafor—CXCR4—Disease—BRAF—hematologic cancer	2.74e-05	0.000219	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CSF2—hematologic cancer	2.72e-05	0.000217	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—FGF1—hematologic cancer	2.72e-05	0.000217	CbGpPWpGaD
Plerixafor—CXCR4—Disease—IL6R—hematologic cancer	2.71e-05	0.000217	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CREBBP—hematologic cancer	2.7e-05	0.000216	CbGpPWpGaD
Plerixafor—Hypersensitivity—Epirubicin—hematologic cancer	2.7e-05	0.000166	CcSEcCtD
Plerixafor—Urticaria—Doxorubicin—hematologic cancer	2.69e-05	0.000166	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—FOXO1—hematologic cancer	2.68e-05	0.000214	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—IL2—hematologic cancer	2.68e-05	0.000214	CbGpPWpGaD
Plerixafor—Abdominal pain—Doxorubicin—hematologic cancer	2.68e-05	0.000165	CcSEcCtD
Plerixafor—Diarrhoea—Methotrexate—hematologic cancer	2.67e-05	0.000165	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PDGFRB—hematologic cancer	2.67e-05	0.000214	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CB—hematologic cancer	2.65e-05	0.000212	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PDGFRA—hematologic cancer	2.63e-05	0.000211	CbGpPWpGaD
Plerixafor—Asthenia—Epirubicin—hematologic cancer	2.62e-05	0.000162	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—JAK1—hematologic cancer	2.62e-05	0.00021	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PRKCG—hematologic cancer	2.62e-05	0.00021	CbGpPWpGaD
Plerixafor—Pruritus—Epirubicin—hematologic cancer	2.59e-05	0.00016	CcSEcCtD
Plerixafor—Dizziness—Methotrexate—hematologic cancer	2.59e-05	0.000159	CcSEcCtD
Plerixafor—CXCR4—Disease—MAP2K1—hematologic cancer	2.58e-05	0.000206	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PIK3CD—hematologic cancer	2.56e-05	0.000205	CbGpPWpGaD
Plerixafor—Diarrhoea—Epirubicin—hematologic cancer	2.5e-05	0.000154	CcSEcCtD
Plerixafor—Hypersensitivity—Doxorubicin—hematologic cancer	2.49e-05	0.000154	CcSEcCtD
Plerixafor—Vomiting—Methotrexate—hematologic cancer	2.49e-05	0.000153	CcSEcCtD
Plerixafor—Rash—Methotrexate—hematologic cancer	2.46e-05	0.000152	CcSEcCtD
Plerixafor—Dermatitis—Methotrexate—hematologic cancer	2.46e-05	0.000152	CcSEcCtD
Plerixafor—CXCR4—Disease—FGF2—hematologic cancer	2.45e-05	0.000196	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IL2RA—hematologic cancer	2.45e-05	0.000196	CbGpPWpGaD
Plerixafor—Headache—Methotrexate—hematologic cancer	2.45e-05	0.000151	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—IL2—hematologic cancer	2.43e-05	0.000195	CbGpPWpGaD
Plerixafor—Asthenia—Doxorubicin—hematologic cancer	2.43e-05	0.00015	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—TERT—hematologic cancer	2.42e-05	0.000194	CbGpPWpGaD
Plerixafor—Dizziness—Epirubicin—hematologic cancer	2.42e-05	0.000149	CcSEcCtD
Plerixafor—CXCR4—Disease—PIK3R1—hematologic cancer	2.42e-05	0.000194	CbGpPWpGaD
Plerixafor—Pruritus—Doxorubicin—hematologic cancer	2.39e-05	0.000148	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PDGFB—hematologic cancer	2.36e-05	0.000189	CbGpPWpGaD
Plerixafor—CXCR4—Disease—JAK2—hematologic cancer	2.35e-05	0.000188	CbGpPWpGaD
Plerixafor—Vomiting—Epirubicin—hematologic cancer	2.33e-05	0.000143	CcSEcCtD
Plerixafor—Nausea—Methotrexate—hematologic cancer	2.32e-05	0.000143	CcSEcCtD
Plerixafor—Diarrhoea—Doxorubicin—hematologic cancer	2.32e-05	0.000143	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—TSC2—hematologic cancer	2.31e-05	0.000185	CbGpPWpGaD
Plerixafor—Rash—Epirubicin—hematologic cancer	2.31e-05	0.000142	CcSEcCtD
Plerixafor—Dermatitis—Epirubicin—hematologic cancer	2.3e-05	0.000142	CcSEcCtD
Plerixafor—CXCR4—Disease—MDM2—hematologic cancer	2.29e-05	0.000184	CbGpPWpGaD
Plerixafor—Headache—Epirubicin—hematologic cancer	2.29e-05	0.000141	CcSEcCtD
Plerixafor—Dizziness—Doxorubicin—hematologic cancer	2.24e-05	0.000138	CcSEcCtD
Plerixafor—CXCR4—Disease—PIK3CB—hematologic cancer	2.23e-05	0.000179	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MTOR—hematologic cancer	2.23e-05	0.000179	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CD4—hematologic cancer	2.23e-05	0.000178	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—FGFR3—hematologic cancer	2.22e-05	0.000178	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MAPK14—hematologic cancer	2.2e-05	0.000176	CbGpPWpGaD
Plerixafor—Nausea—Epirubicin—hematologic cancer	2.17e-05	0.000134	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—ESR1—hematologic cancer	2.16e-05	0.000173	CbGpPWpGaD
Plerixafor—Vomiting—Doxorubicin—hematologic cancer	2.15e-05	0.000133	CcSEcCtD
Plerixafor—Rash—Doxorubicin—hematologic cancer	2.13e-05	0.000132	CcSEcCtD
Plerixafor—Dermatitis—Doxorubicin—hematologic cancer	2.13e-05	0.000132	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—FN1—hematologic cancer	2.13e-05	0.000171	CbGpPWpGaD
Plerixafor—Headache—Doxorubicin—hematologic cancer	2.12e-05	0.000131	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—BAD—hematologic cancer	2.11e-05	0.000169	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NFKBIA—hematologic cancer	2.11e-05	0.000169	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CDKN1B—hematologic cancer	2.1e-05	0.000168	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NOTCH1—hematologic cancer	2.09e-05	0.000167	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CD80—hematologic cancer	2.04e-05	0.000164	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—KIT—hematologic cancer	2.04e-05	0.000163	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CG—hematologic cancer	2.04e-05	0.000163	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—NRAS—hematologic cancer	2.04e-05	0.000163	CbGpPWpGaD
Plerixafor—Nausea—Doxorubicin—hematologic cancer	2.01e-05	0.000124	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PTPN11—hematologic cancer	2e-05	0.00016	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—MAPK3—hematologic cancer	1.95e-05	0.000156	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CREB1—hematologic cancer	1.94e-05	0.000155	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CDKN1A—hematologic cancer	1.93e-05	0.000155	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PTEN—hematologic cancer	1.93e-05	0.000154	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—BRAF—hematologic cancer	1.92e-05	0.000154	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CCL2—hematologic cancer	1.9e-05	0.000152	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IL6R—hematologic cancer	1.89e-05	0.000152	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CREBBP—hematologic cancer	1.89e-05	0.000151	CbGpPWpGaD
Plerixafor—CXCR4—Disease—EP300—hematologic cancer	1.84e-05	0.000147	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MAP2K1—hematologic cancer	1.81e-05	0.000145	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CD—hematologic cancer	1.79e-05	0.000144	CbGpPWpGaD
Plerixafor—CXCR4—Disease—SRC—hematologic cancer	1.79e-05	0.000143	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CA—hematologic cancer	1.78e-05	0.000142	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—KRAS—hematologic cancer	1.76e-05	0.000141	CbGpPWpGaD
Plerixafor—CXCR4—Disease—STAT3—hematologic cancer	1.73e-05	0.000138	CbGpPWpGaD
Plerixafor—CXCR4—Disease—NRAS—hematologic cancer	1.72e-05	0.000138	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—FGF2—hematologic cancer	1.72e-05	0.000137	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3R1—hematologic cancer	1.69e-05	0.000136	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MAPK3—hematologic cancer	1.65e-05	0.000132	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—JAK2—hematologic cancer	1.65e-05	0.000132	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CA—hematologic cancer	1.61e-05	0.000129	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MDM2—hematologic cancer	1.61e-05	0.000129	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MYC—hematologic cancer	1.6e-05	0.000128	CbGpPWpGaD
Plerixafor—CXCR4—Disease—TGFB1—hematologic cancer	1.6e-05	0.000128	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CB—hematologic cancer	1.56e-05	0.000125	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MTOR—hematologic cancer	1.56e-05	0.000125	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—HRAS—hematologic cancer	1.49e-05	0.000119	CbGpPWpGaD
Plerixafor—CXCR4—Disease—KRAS—hematologic cancer	1.48e-05	0.000119	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CDKN1B—hematologic cancer	1.47e-05	0.000117	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—AKT1—hematologic cancer	1.45e-05	0.000116	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CASP3—hematologic cancer	1.44e-05	0.000115	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IL2—hematologic cancer	1.44e-05	0.000115	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—IL6—hematologic cancer	1.43e-05	0.000114	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CCND1—hematologic cancer	1.4e-05	0.000112	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—JUN—hematologic cancer	1.4e-05	0.000112	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PIK3CA—hematologic cancer	1.36e-05	0.000109	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CDKN1A—hematologic cancer	1.35e-05	0.000108	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PTEN—hematologic cancer	1.35e-05	0.000108	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MAPK8—hematologic cancer	1.32e-05	0.000106	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—AKT1—hematologic cancer	1.32e-05	0.000105	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—EP300—hematologic cancer	1.29e-05	0.000103	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HRAS—hematologic cancer	1.26e-05	0.000101	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—SRC—hematologic cancer	1.25e-05	0.0001	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—VEGFA—hematologic cancer	1.22e-05	9.77e-05	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—STAT3—hematologic cancer	1.21e-05	9.67e-05	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NRAS—hematologic cancer	1.21e-05	9.65e-05	CbGpPWpGaD
Plerixafor—CXCR4—Disease—IL6—hematologic cancer	1.21e-05	9.65e-05	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MAPK3—hematologic cancer	1.15e-05	9.24e-05	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MYC—hematologic cancer	1.12e-05	8.99e-05	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TGFB1—hematologic cancer	1.12e-05	8.96e-05	CbGpPWpGaD
Plerixafor—CXCR4—Disease—AKT1—hematologic cancer	1.11e-05	8.9e-05	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—KRAS—hematologic cancer	1.04e-05	8.3e-05	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CA—hematologic cancer	9.53e-06	7.63e-05	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TP53—hematologic cancer	9.22e-06	7.38e-05	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—HRAS—hematologic cancer	8.82e-06	7.06e-05	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IL6—hematologic cancer	8.44e-06	6.76e-05	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—AKT1—hematologic cancer	7.79e-06	6.23e-05	CbGpPWpGaD
